Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

15 oct. 2018 04h19 HE | Source: Biofrontera AG

Biofrontera to Present at the 4th Annual Dawson James Small Cap Growth Stock Conference

Leverkusen, Germany, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today announced that Dr. Hermann...
10 oct. 2018 09h22 HE | Source: Biofrontera AG

Biofrontera announces preliminary unaudited sales revenue for the first nine months of 2018 and increases revenue guidance

Leverkusen, Germany, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), an international biopharmaceutical company, today announced preliminary...
01 oct. 2018 09h08 HE | Source: Biofrontera AG

Swissmedic approves Ameluz® in combination with daylight photodynamic therapy in Switzerland

Leverkusen, Germany, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, announced today that Swissmedic, the...
26 sept. 2018 03h15 HE | Source: Biofrontera AG

Biofrontera starts patient recruitment for U.S. Phase III Trial Evaluating Ameluz® / BF-RhodoLED® for Superficial Basal Cell Carcinoma

Enrollment of 186 patients at 12 study sites in the U.S. startedPhase III trial completion for photodynamic therapy of superficial basal cell carcinoma expected in first half of 2020Filing for...
24 sept. 2018 07h44 HE | Source: Biofrontera AG

Biofrontera to Present at the Cantor Fitzgerald Global Healthcare Conference

Leverkusen, Germany, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today announced that Thomas...
19 sept. 2018 04h03 HE | Source: Biofrontera AG

Biofrontera to present at the Baader Investment Conference

Leverkusen, Germany, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be...
17 sept. 2018 05h17 HE | Source: Biofrontera AG

Biofrontera uses the long summer months to introduce daylight photodynamic therapy (PDT) with Ameluz® in the EU

Leverkusen, Germany, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today announced an update on...
03 sept. 2018 05h35 HE | Source: Biofrontera AG

Correction of news release from August 31, 2018: Biofrontera reports significant revenue growth for the first 6 months of 2018

Leverkusen, Germany, Sept. 03, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
12 juin 2018 08h00 HE | Source: Biofrontera AG

Biofrontera files lawsuit against W.K.T. Zours, Deutsche Balaton AG and further defendants

Leverkusen, Germany, June 12, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced that...
30 mai 2018 08h00 HE | Source: Biofrontera AG

Biofrontera Reports First Quarter 2018 Financial Results

Leverkusen, Germany, May 30, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...

Page précédente